<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038843</url>
  </required_header>
  <id_info>
    <org_study_id>483-005</org_study_id>
    <nct_id>NCT01038843</nct_id>
  </id_info>
  <brief_title>Efficacy Study of VA106483 in Males With Nocturia.</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-titration Study to Determine the Efficacy and Safety of VA106483 in Male Subjects With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vantia Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vantia Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of VA106483 on nocturia related clinical outcomes compared to
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nocturia, defined as waking to urinate at least once per night between periods of sleep, is a
      common complaint which increases with age. VA106483 is a non-peptide drug VA106483 that is
      being developed for the treatment of nocturia in males.

      The purpose of this study is to investigate the effect of VA106483 on the number of times the
      subject needs to get up to urinate (nocturnal void) per night and to determine the effect on
      the time between the subject's bedtime and the time they first wake up to urinate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean number of nocturnal voids per night</measure>
    <time_frame>70 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean duration of first sleep period</measure>
    <time_frame>70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nocturia-related quality of life</measure>
    <time_frame>70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of adverse events</measure>
    <time_frame>70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hyponatraemia</measure>
    <time_frame>70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in safety laboratory parameters</measure>
    <time_frame>70 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>VA106483 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VA106483 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VA106483 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VA106483</intervention_name>
    <description>Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.
Placebo: as above</description>
    <arm_group_label>VA106483 1mg</arm_group_label>
    <arm_group_label>VA106483 2mg</arm_group_label>
    <arm_group_label>VA106483 4mg</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects aged ≥18 years (no upper limit) with nocturia

          -  Generally well (concomitant illness/conditions well controlled)

          -  Serum sodium within the normal limits

          -  Normal or not clinically significant prostate specific antigen levels

          -  Able to comply with the requirements of the study

          -  Provide written informed consent

        Exclusion Criteria:

          -  Prostatic cancer

          -  Signs or symptoms of heart failure

          -  Peripheral pitting oedema extending ≥10 cm above the ankle

          -  Palpable bladder or pelvic mass on abdominal examination

          -  Enuresis or night-time incontinence

          -  Excessive nocturnal void frequency

          -  Sleep disorders

          -  Diabetes insipidus or uncontrolled diabetes mellitus

          -  Presence of blood or glucose in the urine on urinalysis that is clinically significant

          -  Urinary tract infection

          -  Polydipsia

          -  Syndrome of inappropriate antidiuretic hormone secretion

          -  Body mass index ≥35

          -  High calcium levels or low potassium levels

          -  Other protocol defined eligibility criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mira Baron</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rapid Medical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Beccia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical &amp; Clinical Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Blaze</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Broward Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Efros</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accumed Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Gittelman</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Florida Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evan Goldfischer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudson Valley Urology, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Houser</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Urology Team P.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore Johnson II</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kester</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology Center of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Lotenfoe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Discovery Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Earl Martin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin Diagnostic Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. David Mitcheson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bay State Clinical Trials, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tower Urology Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aris Nikas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Texas Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Parkhurst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkhurst Research Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Rankin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avail Clinical Research LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leah Schmidt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genova Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Hezmall</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology Associates of North Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilbur Wells Jnr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Research Center, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Wurzel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grove Hill Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Research Center, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Urology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grove Hill Clinical Research</name>
      <address>
        <city>New Britian</city>
        <state>Connecticut</state>
        <zip>06052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Trials</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Center of Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Broward Research, LLC</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Clinical Research Associates</name>
      <address>
        <city>Bayshore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accumed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Clevland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkhurst Research Organization</name>
      <address>
        <city>Bethany</city>
        <state>Oklahoma</state>
        <zip>73008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of North Texas</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Team P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Texas Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Diagnostic Clinic</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <disposition_first_submitted>June 18, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 18, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 20, 2014</disposition_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VA106483</keyword>
  <keyword>Nocturia</keyword>
  <keyword>males</keyword>
  <keyword>nocturnal voids</keyword>
  <keyword>anti-diuretic</keyword>
  <keyword>hyponatraemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

